ERBB2 and breast cancer: Di Cosimo et al. discovered a five-miRNA signature that possesses significant, independent predictive capability for response to Trastuzumab (area under the curve [AUC]: 0.81) and Lapatinib (AUC: 0.71) in HER2+ breast cancers in the translational research component of the NeoALTTO trial.